The Allogeneic Cell Therapy Manufacturing Market is expected to grow at a 15.0 % CAGR during the forecast period for 2025-2034.
Key Industry Insights & Findings from the Report:
Allogeneic cell therapies involve the transfer of cells from a donor to a patient. Allogeneic cells are collected from various sources, among which blood is the prominent source for allogeneic cells. The small volume of blood comprises many cells that quickly gets multiply.
The key factors driving the growth of the allogeneic cell therapy manufacturing market include the rising elderly population, high prevalence of chronic diseases, the growing demand for personalized treatments, increasing healthcare expenditure, rapid technological advancements in the healthcare sector. Many biopharma companies are collaborating to improve research and development activities in stem cell research, considering the need for allogeneic cell therapies. Likely to propel the growth opportunities for the allogeneic cell therapy manufacturing market in the forthcoming years. For instance, in September 2021, Adaptimmune Therapeutics (UK) partnered with Roche Group member, Genentech, to develop and market allogeneic cell therapies to treat multiple cancer indications.
However, the expensive manufacturing of allogeneic cell therapies and the risks associated with allogeneic cell therapies may hamper the market growth over the forecast period.
The allogeneic cell therapy manufacturing market is classified based on products, scale of operation, and region. By products, the market Induced pluripotent stem cells (iPSC), T-cells and Natural killer (NK) cells, Human pluripotent stem cells (hPSCs), Mesenchymal stem cells (MSC), β-cells, Neurons, Immortalized and engineered cell lines, and Tissue engineered product. The mesenchymal stem cells (MSCS) segment is expected to hold the maximum market share in the coming days due to the increasing R&D activities in stem cell therapies. The market is classified Preclinical Scale Operations, Clinical Scale Operations, and Commercial Scale Operations in terms of scale of operation.
Regionally, the market is studied across North America, Europe, Asia-Pacific, Latin America, and the Middle East & Africa. North America is estimated to hold the maximum share of the market over the forecast years, followed by Europe owing to the growing patients of chronic diseases and surging R&D activities by key players to develop effective allogeneic cell therapies.
| Report Attribute | Specifications |
| Growth Rate CAGR | CAGR of 15.0% from 2025 to 2034 |
| Quantitative Units | Representation of revenue in US$ Million and CAGR from 2025 to 2034 |
| Historic Year | 2021 to 2024 |
| Forecast Year | 2025-2034 |
| Report Coverage | The forecast of revenue, the position of the company, the competitive market structure, growth prospects, and trends |
| Segments Covered | By Products, By Scale of Operations |
| Regional Scope | North America; Europe; Asia Pacific; Latin America; Middle East & Africa |
| Country Scope | U.S.; Canada; U.K.; Germany; China; India; Japan; Brazil; Mexico ;The UK; France; Italy; Spain; South Korea; South East Asia |
| Competitive Landscape | Lonza Group, KBI Biopharma, Inc., Waisman Biomanufacturing, Cell and Gene Therapy Catapult, Thermo Fisher Scientific, Inc., Merck KGaA, Catalent Inc., Oxford Biomedica Plc, Fujifilm Cellular Dynamics, Inc., Wuxi Apptec, Charles River Laboratories International, Inc., The Discovery Labs LLC, ABL, Inc., BioCentriq, Commercializing Living Therapies, and others. |
| Customization Scope | Free customization report with the procurement of the report, Modifications to the regional and segment scope. Particular Geographic competitive landscape. |
| Pricing And Available Payment Methods | Explore pricing alternatives that are customized to your particular study requirements. |
Chapter 1. Methodology and Scope
1.1. Research Methodology
1.2. Research Scope & Assumptions
Chapter 2. Executive Summary
Chapter 3. Global Allogeneic Cell Therapy Manufacturing Market Snapshot
Chapter 4. Global Allogeneic Cell Therapy Manufacturing Market Variables, Trends & Scope
4.1. Market Segmentation & Scope
4.2. Drivers
4.3. Challenges
4.4. Trends
4.5. Investment and Funding Analysis
4.6. Industry Analysis – Porter’s Five Forces Analysis
4.7. Allogeneic Cell Therapy Clinical Trial/Pipeline Analysis
4.8. Impact of Covid-19 Analysis
Chapter 5. Market Segmentation 1: By Product, Estimates & Trend Analysis
5.1. By Products, & Market Share, 2024 & 2034
5.2. Market Size (Value US$ Mn) & Forecasts and Trend Analyses, 2021 to 2034 for the following By Products:
5.2.1. Induced pluripotent stem cells (iPSC)
5.2.2. T-cells and Natural killer (NK) cells
5.2.3. Human pluripotent stem cells (hPSCs)
5.2.4. Mesenchymal stem cells (MSC)
5.2.5. β-cells
5.2.6. Neurons
5.2.7. Immortalized and engineered cell lines
5.2.8. Tissue engineered product
Chapter 6. Market Segmentation 2: By Scale of Operation Estimates & Trend Analysis
6.1. By Scale of Operation & Market Share, 2024 & 2034
6.2. Market Size (Value US$ Mn) & Forecasts and Trend Analyses, 2021 to 2034 for the following By Scale of Operation
6.2.1. Preclinical Scale Operations
6.2.2. Clinical Scale Operations
6.2.3. Commercial Scale Operations
Chapter 7. Allogeneic Cell Therapy Manufacturing Market Segmentation 3: Regional Estimates & Trend Analysis
7.1. North America
7.1.1. North America Allogeneic Cell Therapy Manufacturing Market revenue (US$ Million) estimates and forecasts By Products, 2021-2034
7.1.2. North America Allogeneic Cell Therapy Manufacturing Market revenue (US$ Million) estimates and forecasts By Scale of Operation, 2021-2034
7.1.3. North America Allogeneic Cell Therapy Manufacturing Market revenue (US$ Million) by country, 2021-2034
7.2. Europe
7.2.1. Europe Allogeneic Cell Therapy Manufacturing Market revenue (US$ Million) By Products, 2021-2034
7.2.2. Europe Allogeneic Cell Therapy Manufacturing Market revenue (US$ Million) By Scale of Operation, 2021-2034
7.2.3. Europe Allogeneic Cell Therapy Manufacturing Market revenue (US$ Million) by country, 2021-2034
7.3. Asia Pacific
7.3.1. Asia Pacific Allogeneic Cell Therapy Manufacturing Market revenue (US$ Million) By Products, 2021-2034
7.3.2. Asia Pacific Allogeneic Cell Therapy Manufacturing Market revenue (US$ Million) By Scale of Operation, 2021-2034
7.3.3. Asia Pacific Allogeneic Cell Therapy Manufacturing Market revenue (US$ Million) by country, 2021-2034
7.4. Latin America
7.4.1. Latin America Allogeneic Cell Therapy Manufacturing Market revenue (US$ Million) By Products, (US$ Million) 2021-2034
7.4.2. Latin America Allogeneic Cell Therapy Manufacturing Market revenue (US$ Million) By Scale of Operation, (US$ Million) 2021-2034
7.4.3. Latin America Allogeneic Cell Therapy Manufacturing Market revenue (US$ Million) by country, 2021-2034
7.5. Middle East & Africa
7.5.1. Middle East & Africa Allogeneic Cell Therapy Manufacturing Market revenue (US$ Million) By Products, (US$ Million) 2021-2034
7.5.2. Middle East & Africa Allogeneic Cell Therapy Manufacturing Market revenue (US$ Million) By Scale of Operation, (US$ Million) 2021-2034
7.5.3. Middle East & Africa Allogeneic Cell Therapy Manufacturing Market revenue (US$ Million) by country, 2021-2034
Chapter 8. Competitive Landscape
8.1. Major Mergers and Acquisitions/Strategic Alliances
8.2. Company Profiles
8.2.1. Lonza Group
8.2.2. KBI Biopharma, Inc.
8.2.3. Waisman Biomanufacturing
8.2.4. Cell and Gene Therapy Catapult
8.2.5. Thermo Fisher Scientific, Inc.
8.2.6. Merck KGaA
8.2.7. Catalent Inc.
8.2.8. Lonza Group
8.2.9. Oxford Biomedica Plc
8.2.10. Fujifilm Cellular Dynamics, Inc.
8.2.11. Wuxi Apptec
8.2.12. Charles River Laboratories International, Inc.
8.2.13. The Discovery Labs LLC
8.2.14. ABL, Inc.
8.2.15. BioCentriq
8.2.16. Commercializing Living Therapies
8.2.17. Other Prominent Players
Global Allogeneic Cell Therapy Manufacturing Market, by Products, 2019-2030 (Value US$ Mn)
Global Allogeneic Cell Therapy Manufacturing Market, by Scale of Operation, 2019-2030 (Value US$ Mn)
Global Allogeneic Cell Therapy Manufacturing Market, by Region, 2019-2030 (Value US$ Mn)
North America Allogeneic Cell Therapy Manufacturing Market, by Country, 2019-2030 (Value US$ Mn)
Europe Allogeneic Cell Therapy Manufacturing Market, by Country, 2019-2030 (Value US$ Mn)
Asia Pacific Allogeneic Cell Therapy Manufacturing Market, by Country, 2019-2030 (Value US$ Mn)
Latin America Allogeneic Cell Therapy Manufacturing Market, by Country, 2019-2030 (Value US$ Mn)
Middle East & Africa Allogeneic Cell Therapy Manufacturing Market, by Country, 2019-2030 (Value US$ Mn)
Competitive Landscape
Latest Strategic Developments